Saridegib

Saridegib
Names
	IUPAC name N-((2S,3R,3aS,3′R,4a′R,6S,6a′R,6b′S,7aR,12a′S,12b′S)-3,6,11′,12b′-tetramethyl-2′,3a,3′,4,4′,4a′,5,5′,6,6′,6a′,6b′,7,7a,7′,8′,10′,12′,12a′,12b′-icosahydro-1′H,3H-spiro[furo[3,2-b]pyridine-2,9'-naphtho[2,1-a]azulen]-3'-yl)methanesulfonamide
	Other names saridegib
Identifiers
CAS Number	1037210-93-7 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL538867;
ChemSpider	26353073;
IUPHAR/BPS	8198;
KEGG	D10324;
PubChem CID	25027363;
UNII	JT96FPU35X ;
CompTox Dashboard (EPA)	DTXSID40146032 ;
	SMILES [H][C@]12[C@@]([C@@]3([H])C(C2)=C(C)C[C@@]4(O[C@@](C[C@H](C)CN5)([H])[C@]5([H])[C@H]4C)CC3)([H])CC[C@]6([H])C[C@H](NS(C)(=O)=O)CC[C@@]61C;
Properties
Chemical formula	C29H48N2O3S
Molar mass	504.77 g·mol−1
Pharmacology
Routes of; administration	Oral
Legal status	Investigational;
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

Saridegib, also known as IPI-926, is an experimental drug candidate undergoing clinical trials for the treatment of various types of cancer, including hard-to-treat hematologic malignancies such as myelofibrosis and ligand-dependent tumors such as chondrosarcoma.[1] IPI-926 exhibits its pharmacological effect by inhibition of the G protein-coupled receptor smoothened, a component of the hedgehog signaling pathway.[2] Chemically, it is a semi-synthetic derivative of the alkaloid cyclopamine. The process begins with cyclopamine extracted from harvested Veratrum californicum which is taken through a series of alterations resulting in an analogue of the natural product cyclopamine, making IPI-926 the only compound in development/testing that is not fully synthetic.[2]

Saridegib is a member of a class of anti-cancer compounds known as hedgehog pathway inhibitors.

References

"Pipeline: IPI-926". Infinity Pharmaceuticals. Archived from the original on 2012-01-19.CS1 maint: unfit url (link)
Tremblay, MR; Lescarbeau, A; Grogan, MJ; Tan, E; Lin, G; Austad, BC; Yu, LC; Behnke, ML; et al. (2009). "Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926)". Journal of Medicinal Chemistry. 52 (14): 4400–18. doi:10.1021/jm900305z. PMID 19522463.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Pipeline926-1] "Pipeline: IPI-926". Infinity Pharmaceuticals. Archived from the original on 2012-01-19.CS1 maint: unfit url (link)

[Tremblay-2] Tremblay, MR; Lescarbeau, A; Grogan, MJ; Tan, E; Lin, G; Austad, BC; Yu, LC; Behnke, ML; et al. (2009). "Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926)". Journal of Medicinal Chemistry. 52 (14): 4400–18. doi:10.1021/jm900305z. PMID 19522463.